Market research
AUROPHARMA.NSE Aurobindo Pharma Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 967B
- P/E ratio
- 26.22
- Analyst target
- 1689.5925
- Dividend yield
- Not available
- Beta
- 0.03
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE406A01037
- Market cap
- 967B
- P/E ratio
- 26.22
- Analyst target
- 1689.5925
- Dividend yield
- Not available
- Beta
- 0.03
About
About Aurobindo Pharma Limited
Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas. It also provides ointments, creams, gels, powders, transdermal, and lotions; antiretroviral drugs for PLHIV & CLHIV; and injectable products, including Penems, Penicillin, Cephalosporin, ophthalmic, inhalation, oncology, and hormone products. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AUROPHARMA.NSE discussion.
5 years, 5 months ago
Aurobindo Pharma Limited is currently in a long term uptrend where the price is trading 6.4% above its 200 day moving average.
From a valuation standpoint, the stock is 56.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.1.
Aurobindo Pharma Limited's total revenue rose by 7.8% to $64B since the same quarter in the previous year.
Its net income has increased by 317.7% to $29B since the same quarter in the previous year.
Finally, its free cash flow fell by 5.6% to $21B since the same quarter in the previous year.
Based on the above factors, Aurobindo Pharma Limited gets an overall score of 4/5.